What do systematic reviews say?

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 196 participants
  Moderate

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Sclerotherapy plus compression showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy alone (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.93 [0.41, 2.07]
  2 studies · 196 participants
  Moderate

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Sclerotherapy plus compression showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy alone (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 1.84 [0.17, 19.62]
  1 study · 96 participants
  Low

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 93 participants
  Low

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 348 participants
  Moderate

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

Sclerotherapy (hypertonic saline) probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.74 [0.59, 0.93]
  2 studies · 288 participants
  Moderate

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

Sclerotherapy (hypertonic saline) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.89 [0.58, 1.36]
  2 studies · 288 participants
  Moderate

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 348 participants
  Moderate

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 125 participants
  Low

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.49 [0.09, 2.5]
  2 studies · 125 participants
  Low

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.31 [0.01, 7.53]
  1 study · 99 participants
  Low

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Sclerotherapy (chromated glycerin) showed no clear difference in pain ( compared with sclerotherapy (any sclerosant) (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 1.5 [0.3, 7.55]
  1 study · 26 participants
  Low

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found